Table 3 Multivariate analysis of factors and Pdet.Qmax at different time points in SCI patients with detrusor BoNT-A injection

From: Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia

Variable Cases Pdet.Qmax (cm H 2 O) P-value
   Baseline 3 months 6 months  
Level of injury
 C-spine 13 37±21.2 19.4±14.8 12.2±11.3 0.874 (3 months vs BL)
 T-spine 19 43.2±21.9 29.7±18.4 35±26.6 0.44 (6 months vs BL)
 L-spine 6 41.7±22.4 29.2±16.6 38.2±28.7  
Baseline Pdet
 Pdet 40 17 21.4±12.5 23.7±14.3 26.7±26.2 0.00 (3 months vs BL)
 Pdet>40 21 56.4±11.7 28.1±19.4 31.6±25.5 0.007 (6 months vs BL)
Baseline DSD type
 Type 1 14 36.4±17.1 30.1±11.5 34.9±29.3 0.26 (3 months vs BL)
 Type 2 14 38.8±17.1 23.1±19.2 31.3±25.3 0.24 (6 months vs BL)
 Type 3 10 49.6±21.9 27.9±22.2 19.9±20.4  
Baseline PVR
100 20 40±16.1 26.3±14.4 31.7±24.6 0.83 (3 months vs BL)
>100 18 41.6±26.4 25.9±20.3 26.5±27.2 0.61 (6 months vs BL)
Gender
 Male 17 35.4±21.4 20.7±15.0 23.9 ±20.8 0.99 (3 months vs BL)
 Female 21 45.1±20.7 30.5±18.0 33.9±28.7 0.807 (6 months vs BL)
Compliance
30 27 42.1±22.0 30.2±18.1 31.2±27.4 0.32 (3 months vs BL)
>30 11 37.4±20.2 16.2±9.7 24.4±20.1 0.39 (6 months vs BL)
ASIA scale
 Non-A 12 43.3±24.2 25.2±16.5 31±23.0 0.58 (3 months vs BL)
 A 26 39.6±20.3 26.5±17.9 28.7±27.0 0.62 (6 months vs BL)
Dosage
 200 U 11 43.9±22.1 26.1±17.2 48.3±12.6 0.07 (3 months vs BL)
 300 U 11 47.6±13 24.4±19 25.9±18.9 0.026 (6 months vs BL)
  1. Abbreviations: ASIA, American Spinal Injury Association; BL, baseline; BoNT-A, botulinum toxin A; DSD, detrusor sphincter dyssynergia; Pdet.Qmax, detrusor pressure at maximum ow rate; PVR, post-void residual; UDI-6, urogenital distress inventory 6-item short form.[2]P-value using paired Student's t-tests for dichotomous variables and analysis of variance for more than two variables to compare changes of Pdet.Qmax among patients with different variables.